Biognosys, a leading inventor and developer of mass spectrometry
(MS)-based proteomics solutions, announced today their attendance
at the Human Proteome Organization (HUPO) World Congress from
September 17 to September 21 in Busan, South Korea.
During the Technological Advancements session on Tuesday,
September 19, Biognosys’ Chief Technology Officer Dr. Lukas Reiter
will give a Keynote presentation “Bottom-up Proteomics using DIA”
on the evolution, recent developments, and future of
data-independent acquisition (DIA) in MS-based proteomics.
Biognosys also will present ten posters showcasing technological
innovations and novel scientific data with its proprietary
proteomics research services, software, and kits. Biognosys’ team
of scientific experts will be exhibiting and offering software
demos at booth #408.
Biognosys’ strategic partner Bruker will introduce novel
concepts for the timsTOF platform and Bruker ProteoScape™ software
suite, forging synergies with Biognosys’ Spectronaut® software and
iRT Kit to offer customers enhanced capabilities for high-fidelity,
high-throughput proteomics.
“I am thrilled to present significant advances with Biognosys’
MS proteomics technology and solutions that bring us again closer
to making the proteome truly actionable for research, drug
development, and clinical decision-making,”
commented Dr. Lukas
Reiter. “Our continuously improving software and
well-established kits empower users of major MS instruments to
perform cutting-edge, hassle-free workflows for deep,
high-throughput, reproducible proteomics research in-house. Our CRO
services provide biopharma and diagnostics customers with
unparalleled precision and insights to expedite biomarker discovery
and drug development.”
Spectronaut® 18:
Industry-leading depth, throughput, and efficiency for DIA data
analysis
Spectronaut 18, the latest version of Biognosys’ flagship
software, offers a significantly further improved identification
rate and quantification quality, as well as various new features
that make DIA proteomics more efficient and scalable. At HUPO,
Biognosys will present three posters highlighting powerful
applications of Spectronaut 18 for comprehensive proteome
quantification. Remarkable innovations include the utilization of
directDIA+™ for faster, library-free analysis, and deep learning
with DeepQuant to enhance the quantification of low-abundant
proteins through a neural network for interference correction of
precursor quantities.
TrueDiscovery®: Proven
precision for biomarker discovery in oncology and
neuroscience
Biognosys will present three posters showcasing biomarker
discovery and drug development research conducted with esteemed
collaborators, including Genmab, Johns Hopkins University School of
Medicine, Stanford University, and University of Zuerich. The
studies utilized Biognosys’ TrueDiscovery platform for unbiased
proteomics and collectively demonstrate the quantitative precision,
robustness, and wide applicability of MS proteomics for oncology
and neuroscience research. A fourth poster evaluates the
technological and biological complementarity of TrueDiscovery and
the Olink® Explore affinity-based platform of Olink Proteomics AB
for plasma proteomics.
TrueTarget®: Efficient
target deconvolution and binding sites mapping in drug
discovery
Biognosys’ TrueTarget platform leverages limited proteolysis
mass spectrometry (LiP-MS) to facilitate drug target identification
and validation. A first poster, in collaboration with InterAx,
demonstrates TrueTarget’s unique capabilities in deconvoluting the
target of a G-Protein Coupled Receptor (GPCR) antagonist, mapping
its binding sites, and providing structural insights on the
mechanism of action. A second poster, in collaboration with Samsara
Therapeutics, illustrates how target deconvolution with TrueTarget,
followed by unbiased proteome profiling with TrueDiscovery, enabled
the efficient identification and validation of target proteins and
enhanced understanding of biological systems in novel therapeutic
development.
Biognosys and Bruker: Seamless workflows for
dia-PASEF® and QC on
timsTOF
To ensure optimal MS performance, Bruker introduces TwinScape™,
a digital twin for the timsTOF platform, interlinked with
ProteoScape software to support real-time quality control (QC) with
the Biognosys iRT Kit. The peptides in the iRT Kit have been
carefully optimized for stability, sensitivity and retention time
spacing, and this iRT Kit can now be used for system QC in Bruker’s
proteomics software ProteoScape. Biognosys’ Head of Business
Development – Products, Dr. Sira Echevarria, will present how
Spectronaut offers improved library-free proteomics analysis for
dia-PASEF using directDIA+ during Bruker’s HUPO lunch seminar on
Tuesday, September 19.
Visit biognosys.com/hupo-2023 for a complete overview of
Biognosys’ presence at HUPO. Posters will be available for download
from Friday, September 22.
About Spectronaut®
Spectronaut is Biognosys’ flagship data analysis software for
data-independent acquisition (DIA) mass spectrometry (MS) based
proteomics.
The software employs advanced Search and Artificial Intelligence
(AI) algorithms to translate data into actionable insights for life
science research. Spectronaut enables reproducible and precise
quantification of thousands of proteins in a single experiment and
provides multi-dimensional insights into protein expression,
function, and structure across all major biological species and
sample types. For more information, visit spectronaut.com.
About
TrueDiscovery®
The Biognosys TrueDiscovery platform offers integrated
proteomics solutions across the entire drug development
pipeline.
TrueDiscovery is powered by Hyper Reaction Monitoring (HRM) mass
spectrometry, an advanced Data Independent Acquisition (DIA)-based
protein quantification technology co-invented and patented by
Biognosys.
TrueDiscovery is the only platform that searches the complete
proteome to quantify thousands of the most relevant proteins,
including an unlimited number of proteoforms. The platform enables
the deepest unbiased profiling of tissue and biofluids proteomes
with unbeatable specificity on a large scale. The generated data
are highly reproducible and easily transferrable to clinical
assays. Studies can be performed in a GLP certified and GCP
compliant environment. For more information, visit
truediscovery.bio.
About TrueTarget®
The Biognosys TrueTarget proteomics platform uniquely addresses
the most pressing challenges in early drug discovery by identifying
on- and off-targets to accelerate and de-risk drug development
throughout the pipeline.
TrueTarget is powered by Limited Proteolysis Mass Spectrometry
(LiP-MS), a proprietary, patented chemoproteomics technology
co-developed by Biognosys. TrueTarget is the only tool to probe
structural changes across the complete proteome with peptide-level
resolution, providing unique insights into compound binding and
target identification.
The platform enables elucidating mechanisms of action and
revealing unanticipated toxicities. For more information, visit
truetarget.bio
About Biognosys
At Biognosys, we believe that deep proteome insights hold the
key to breakthrough discoveries that transform science for better
lives. With our versatile portfolio of next-generation proteomics
solutions, including the TrueDiscovery®, TrueTarget®, and
TrueSignature® research service platforms, our flagship software
Spectronaut®, and the PQ500™ kit, we make the proteome actionable
to empower research, drug development, and clinical
decision-making. Our solutions provide a multi-dimensional view of
protein expression, function, and structure in all biological
species and sample types. Our unique, patented technologies utilize
high-resolution mass spectrometry to quantify thousands of proteins
with industry-leading precision, depth, and throughput. Through our
strategic partnership with Bruker (Nasdaq: BRKR), we make
proteomics globally accessible. For more information, visit
biognosys.com.
Media Contact
Yves Serroen
Head of Marketing and Communications
Phone +41 (0) 44 244 50 07
yves.serroen@biognosys.com
Bruker (NASDAQ:BRKR)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Bruker (NASDAQ:BRKR)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024